The trial met the primary and all key secondary endpoints, demonstrating comparable efficacy to IV morphine.
The company plans to file its U.S. marketing application in Q4.
Monday, June 3, 2019
Avenue up on positive late-stage study of IV tramadol
Thinly traded nano cap Avenue Therapeutics (NASDAQ:ATXI) is up 16% premarket on light volume in reaction to a successful second Phase 3 clinical trial evaluating IV tramadol for the treatment of postoperative pain following abdominoplasty (tummy tuck) surgery.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.